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comparative purposes. Therefore, the final sample considered in the effectiveness analysis comprised 110 patients. There were 55 patients in the diltiazem group and 55 in the placebo group. The mean age of the patients was 42.2 (+/-10.6) years (age range: 14 -72) in the diltiazem group and 41.8 (+/-9.6) years (age range: 21 -67) in the placebo group. There were 39 women in each of the two groups.
Study design
This was a prospective, double-blind, placebo-controlled randomised trial that was conducted in three hospitals (Queen Mary, Queen Elizabeth and Princess Margaret hospitals). At each hospital the patients were randomised in blocks. The methods of randomisation and blinding were not reported. The length of follow-up was 6 months. The loss to follow-up was unclear but it appears to have been negligible.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The outcome measures used were: the reduction in cyclosporin dosage; blood cyclosporin concentrations, dosages and serum creatinine values just prior to ceasing trial medication, and up to 12 weeks after;
the creatinine values at 3 and 6 months; the occurrence of adverse events or complications; the requirement for inpatient or outpatient care, or relevant clinical investigations; deaths; rejection episodes; medication discontinuation; and quality of life, which was assessed through the SF-36 questionnaire.
The study groups were comparable at trial entry in terms of the demographics, presence of co-morbidities and disease characteristics. However, significantly more patients had diabetes mellitus in the diltiazem group (10) than in the placebo group (1), (p=0.01).
Effectiveness results
The mean daily reduction in cyclosporin dosage was 30.4% (+/-19.3) in the diltiazem group and 16% (+/-23.6) in the placebo group (95% confidence interval (CI) for the difference: 14.4% +/-8.1; p<0.001).
When data from a patient who developed tuberculosis were omitted, the mean daily reduction in cyclosporin dosage was 30.4% (+/-19.3) in the diltiazem group and 18.1% (+/-17.6) in the placebo group (95% CI for the difference: 12.3% +/-7; p<0.001).
The mean creatinine value was 140 (+/-45) micromol/L in the diltiazem group and 136 (+/-29) micromol/L in the placebo group at 3 months. The corresponding figures at 6 months were 131 (+/-37) micromol/L (diltiazem) and 134 (+/-28) micromol/L (placebo), respectively.
For diltiazem versus placebo group, the blood cyclosporin concentration levels were: 157 versus 142 ng/mL just before, or on the day of stopping the trial medication;
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Clinical conclusions
The effectiveness analysis showed that the use of diltiazem was safe and effective in reducing cyclosporin use among renal allograft patients.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was conducted.
Direct costs
Discounting was irrelevant since the costs per patient were incurred during 6 months. The unit costs were not reported separately from the quantities of resources used. The economic evaluation focused only on the cost of medication. Other categories of costs (i.e. investigative tests, hospital inpatient days and outpatient visits) were not statistically different and were not included in the economic analysis. The cost/resource boundary of the study was not explicitly stated, but it appears to have been that of the hospital. Resource use was estimated using actual data derived from the sample of patients involved in the effectiveness study. Local cost estimates were used. These were presumably estimated from the three study hospitals in 1999.
Statistical analysis of costs
The costs were presented as mean values with 95% CIs. Statistical tests were performed to test the significance of differences in the estimated costs.
Indirect Costs
The indirect costs were not considered.
Currency
Hong Kong dollars (HK$). The conversion rate from UK pounds sterling () was assumed to be 1 = HK$12.2.
Sensitivity analysis
A sensitivity analysis was carried out in which the price of the medication was varied. More recent local prices of diltiazem (updated to April 2002) were used.
